Raloxifene and alendronate containing thin mesoporous titanium oxide films improve implant fixation to bone

Harmankaya, Necati; Karlsson, Johan; Palmquist, Anders; Halvarsson, Mats; Igawa, Kazuyo; Andersson, Martin; Tengvall, Pentti

doi:10.1016/j.actbio.2013.02.040

Cited by 63 publications

(72 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The osteogenic effect was evaluated by quantitative polymerase chain reaction (qPCR), removal torque, histomorphometry, and ultrastructural interface analysis. The drug-loaded implants showed significantly improved bone fixation and stronger bone-remodeling activity when compared with controls and ALD-loaded implants (Harmankaya et al, 2013).…”

Section: Implantsmentioning

confidence: 95%

Bisphosphonates: therapeutics potential and recent advances in drug delivery

et al. 2014

View full text Add to dashboard Cite

Context: Bisphosphonates (BPs) are widely used for prevention and treatment of osteoporosis. BPs are known as gold standard for osteoporosis (OP) treatment due to their positive results in clinical studies. But some serious side effects are associated with BPs like gastrointestinal adverse effect i.e. esophagitis and ulcer of esophagus. Oral bioavailability (BA) of BPs ranges from 0.6 to 1% due to poor absorption through gastrointestinal tract (GIT). Objective: The main objective of this review is to explore the role of novel drug delivery systems (DDSs) for the delivering of BPs and minimizing the drawbacks associated with them. Methods: The current review is focusing on classification, mechanism of action, and limitations of BPs, and is also dwelling on the use of novel DDSs like nanoparticles, liposomes, topical, transdermal systems, implants, bisphosphonate osteotropic DDS (BP-ODDS), microspheres, and calcium phosphate cements (CPCs) for BPs. This review also gives a critically reviewed compilation of the various in vitro and in vivo studies conducted till date. Conclusion: On the basis of the exhaustive literature, it has been found that the novel DDS minimizes the side effects associated with BPs and enhances the BA. The advance drug delivery has a greater impact on reducing the undesirable effects and increasing the BA of BPs.

show abstract

Section: Implantsmentioning

confidence: 95%

Bisphosphonates: therapeutics potential and recent advances in drug delivery

et al. 2014

View full text Add to dashboard Cite

show abstract

“…53 The integration of such implants was further improved using osteoporosis drugs, alendronate and raloxifene, which were administrated locally from the mesoporous film. 23 Both the mechanical stability and the amount of formed bone were shown to increase. The results from this present study also showed an additional favorable property of the mesoporous films, that is, that they also decreased bacterial adhesion, both with and without the use of antibiotics.…”

mentioning

confidence: 99%

“…The use of mesoporous coatings on medical devices has also been highlighted in previous studies for improving osseointegration using local administration of osteoporosis-reversing drugs. 23 Tunable textural properties, high surface area, and pore volume are typical properties of mesoporous materials, which make them suitable candidates for drug-delivery purposes. [24][25][26][27][28][29][30] For example, a sustained release of cephalothin from mesoporous titania-coated implants in vitro has recently been reported.…”

Section: Introductionmentioning

confidence: 99%

“…48 Similar behavior of bacterial attachment responses by changing the nanotopography have previously been observed regarding the use of carbon nanotubes and nanostructured gold surfaces. 23,49 Moreover, the formed mesoporous materials have a long-range order, something that has been previously shown to affect cell responses. 50 This implies that apart from the traditional means of characterizing biomaterials, both when it comes to tissue integration properties as well as antimicrobial behaviors, studies should be performed with respect to ordering and size of nanostructured domains.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Antimicrobial performance of mesoporous titania thin films: role of pore size, hydrophobicity, and antibiotic release

Atefyekta¹,

Ercan²,

Karlsson³

et al. 2016

IJN

View full text Add to dashboard Cite

Implant-associated infections are undesirable complications that might arise after implant surgery. If the infection is not prevented, it can lead to tremendous cost, trauma, and even life threatening conditions for the patient. Development of an implant coating loaded with antimicrobial substances would be an effective way to improve the success rate of implants. In this study, the in vitro efficacy of mesoporous titania thin films used as a novel antimicrobial release coating was evaluated. Mesoporous titania thin films with pore diameters of 4, 6, and 7 nm were synthesized using the evaporation-induced self-assembly method. The films were characterized and loaded with antimicrobial agents, including vancomycin, gentamicin, and daptomycin. Staphylococcus aureus and Pseudomonas aeruginosa were used to evaluate their effectiveness toward inhibiting bacterial colonization. Drug loading and delivery were studied using a quartz crystal microbalance with dissipation monitoring, which showed successful loading and release of the antibiotics from the surfaces. Results from counting bacterial colony-forming units showed reduced bacterial adhesion on the drug-loaded films. Interestingly, the presence of the pores alone had a desired effect on bacterial colonization, which can be attributed to the documented nanotopographical effect. In summary, this study provides significant promise for the use of mesoporous titania thin films for reducing implant infections.

show abstract

“…Moreover, in a previous study, it was demonstrated that mesoporous titania has good biomechanical stability toward the shearing forces that arises during implantation procedure, which also strengthen its usefulness as an implant coating. 26 It has also been shown in vivo that an enhanced osseointegration can be achieved using mesoporous titania with a pore size of 6 nm as the drug delivery system [27][28][29] and that it provides a sustained drug delivery in vivo. 30 Quartz crystal microbalance with dissipation (QCM-D) is a suitable technique for in situ monitoring of adsorption-and desorption-kinetics of molecules to/from surfaces, which provides a high mass sensitivity.…”

Section: Introductionmentioning

confidence: 99%

Controlling drug delivery kinetics from mesoporous titania thin films by pore size and surface energy

Karlsson¹,

Atefyekta²,

Andersson³

2015

IJN

View full text Add to dashboard Cite

The osseointegration capacity of bone-anchoring implants can be improved by the use of drugs that are administrated by an inbuilt drug delivery system. However, to attain superior control of drug delivery and to have the ability to administer drugs of varying size, including proteins, further material development of drug carriers is needed. Mesoporous materials have shown great potential in drug delivery applications to provide and maintain a drug concentration within the therapeutic window for the desired period of time. Moreover, drug delivery from coatings consisting of mesoporous titania has shown to be promising to improve healing of bone-anchoring implants. Here we report on how the delivery of an osteoporosis drug, alendronate, can be controlled by altering pore size and surface energy of mesoporous titania thin films. The pore size was varied from 3.4 nm to 7.2 nm by the use of different structure-directing templates and addition of a swelling agent. The surface energy was also altered by grafting dimethylsilane to the pore walls. The drug uptake and release profiles were monitored in situ using quartz crystal microbalance with dissipation (QCM-D) and it was shown that both pore size and surface energy had a profound effect on both the adsorption and release kinetics of alendronate. The QCM-D data provided evidence that the drug delivery from mesoporous titania films is controlled by a binding–diffusion mechanism. The yielded knowledge of release kinetics is crucial in order to improve the in vivo tissue response associated to therapeutic treatments.

show abstract

Raloxifene and alendronate containing thin mesoporous titanium oxide films improve implant fixation to bone

Cited by 63 publications

References 43 publications

Bisphosphonates: therapeutics potential and recent advances in drug delivery

Bisphosphonates: therapeutics potential and recent advances in drug delivery

Antimicrobial performance of mesoporous titania thin films: role of pore size, hydrophobicity, and antibiotic release

Controlling drug delivery kinetics from mesoporous titania thin films by pore size and surface energy

Contact Info

Product

Resources

About

Raloxifene and alendronate containing thin mesoporous titanium oxide films improve implant fixation to bone

Cited by 63 publications

References 43 publications

Bisphosphonates: therapeutics potential and recent advances in drug delivery

Bisphosphonates: therapeutics potential and recent advances in drug delivery

Antimicrobial performance of mesoporous titania thin films: role of pore size, hydrophobicity, and antibiotic release

Controlling drug delivery kinetics from mesoporous titania thin films by pore size and&nbsp;surface energy

Contact Info

Product

Resources

About

Controlling drug delivery kinetics from mesoporous titania thin films by pore size and surface energy